Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Hemodynamic changes during cardiac resynchronization therapy.

Nägele H, Azizi M, Castel MA.

Clin Cardiol. 2007 Mar;30(3):141-3.

2.

Feasibility, safety, and mid-term efficacy of cardiac resynchronization therapy in patients with severe heart failure and ventricular conduction delay: Chulalongkorn experience.

Sunsaneewitayakul B, Sitthisook S, Sangwatanaroj S, Prechawat S, Songmuang SB.

J Med Assoc Thai. 2007 Jul;90(7):1458-66.

PMID:
17710992
3.

Effects of intravenous nesiritide on pulmonary vascular hemodynamics in pulmonary hypertension.

Michaels AD, Chatterjee K, De Marco T.

J Card Fail. 2005 Aug;11(6):425-31.

PMID:
16105633
4.

Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial.

Cleland J, Freemantle N, Ghio S, Fruhwald F, Shankar A, Marijanowski M, Verboven Y, Tavazzi L.

J Am Coll Cardiol. 2008 Aug 5;52(6):438-45. doi: 10.1016/j.jacc.2008.04.036.

5.
6.

Functional capacity and changes in the neurohormonal and cytokine status after long-term CRT in heart failure patients.

Seifert M, Schlegl M, Hoersch W, Fleck E, Doelger A, Stockburger M, Butter C.

Int J Cardiol. 2007 Sep 14;121(1):68-73. Epub 2007 Jun 20.

PMID:
17582527
7.

Long-term retention of cardiac resynchronization therapy.

Knight BP, Desai A, Coman J, Faddis M, Yong P.

J Am Coll Cardiol. 2004 Jul 7;44(1):72-7.

8.

Chronic cardiac resynchronization therapy reverses cardiac remodelling and improves invasive haemodynamics of patients with severe heart failure on optimal medical treatment.

Inage T, Yoshida T, Hiraki T, Ohe M, Takeuchi T, Nagamoto Y, Fukuda Y, Gondo T, Imaizumi T.

Europace. 2008 Mar;10(3):379-83. doi: 10.1093/europace/eum297. Epub 2008 Jan 28.

PMID:
18227354
9.

Brain natriuretic peptide levels and response to cardiac resynchronization therapy in heart failure patients.

Delgado RM, Palanichamy N, Radovancevic R, Vrtovec B, Radovancevic B.

Congest Heart Fail. 2006 Sep-Oct;12(5):250-3. Erratum in: Congest Heart Fail. 2006 Nov-Dec;12(6):342. Vrtotec, Bojan [corrected to Vrtovec, Bojan].

10.

Dual-site left ventricular cardiac resynchronization therapy.

Padeletti L, Colella A, Michelucci A, Pieragnoli P, Ricciardi G, Porciani MC, Tronconi F, Hettrick DA, Valsecchi S.

Am J Cardiol. 2008 Dec 15;102(12):1687-92. doi: 10.1016/j.amjcard.2008.08.016. Epub 2008 Sep 20.

PMID:
19064025
11.

Decrease of plasma N-terminal pro beta-type natriuretic peptide as a predictor of clinical improvement after cardiac resynchronization therapy for heart failure.

Ding LG, Hua W, Zhang S, Chu JM, Chen KP, Wang Y, Wang FZ, Chen X.

Chin Med J (Engl). 2009 Mar 20;122(6):617-21.

PMID:
19323922
12.

Cardiac resynchronisation therapy in patients with end-stage heart failure--long-term follow-up.

Faran A, Lewicka-Nowak E, Dabrowska-Kugacka A, Kempa M, Tybura S, Szwoch M, Królak T, Raczak G.

Kardiol Pol. 2008 Jan;66(1):19-26; discussion 27.

13.

A mechanistic investigation into how long-term resynchronization therapy confers ongoing cardiac functional benefits and improved exercise capacity.

Schlosshan D, Barker D, Lewis N, Pepper C, Tan LB.

Am J Cardiol. 2009 Mar 1;103(5):701-8. doi: 10.1016/j.amjcard.2008.10.041. Epub 2009 Jan 15.

PMID:
19231337
14.

Acute and chronic effects of cardiac resynchronization in patients developing heart failure with long-term pacemaker therapy for acquired complete atrioventricular block.

Shimano M, Tsuji Y, Yoshida Y, Inden Y, Tsuboi N, Itoh T, Suzuki H, Muramatsu T, Okada T, Harata S, Yamada T, Hirayama H, Nattel S, Murohara T.

Europace. 2007 Oct;9(10):869-74. Epub 2007 Jun 8.

PMID:
17557768
15.

Long-term effects of upgrading from right ventricular pacing to cardiac resynchronization therapy in patients with heart failure.

Foley PW, Muhyaldeen SA, Chalil S, Smith RE, Sanderson JE, Leyva F.

Europace. 2009 Apr;11(4):495-501. doi: 10.1093/europace/eup037.

PMID:
19307283
16.

Diastolic filling pattern and left ventricular diameter predict response and prognosis after cardiac resynchronisation therapy.

Gradaus R, Stuckenborg V, Löher A, Köbe J, Reinke F, Gunia S, Vahlhaus C, Breithardt G, Bruch C.

Heart. 2008 Aug;94(8):1026-31. Epub 2007 Nov 5.

PMID:
17984216
17.

Effect of right ventricular lead location on response to cardiac resynchronization therapy in patients with end-stage heart failure.

Haghjoo M, Bonakdar HR, Jorat MV, Fazelifar AF, Alizadeh A, Ojaghi-Haghjghi Z, Esmaielzadeh M, Sadr-Ameli MA.

Europace. 2009 Mar;11(3):356-63. doi: 10.1093/europace/eun375. Epub 2009 Jan 9.

PMID:
19136489
18.

Cardiac resynchronization therapy in patients with end-stage inotrope-dependent class IV heart failure.

Herweg B, Ilercil A, Cutro R, Dewhurst R, Krishnan S, Weston M, Barold SS.

Am J Cardiol. 2007 Jul 1;100(1):90-3. Epub 2007 May 15.

PMID:
17599447
19.

Human B-natriuretic peptide improves hemodynamics and renal function in heart transplant patients immediately after surgery.

Feldman DS, Ikonomidis JS, Uber WE, Van Bakel AB, Pereira NL, Crumbley AJ 3rd, Tann SM.

J Card Fail. 2004 Aug;10(4):292-6.

PMID:
15309694
20.

Blood B-type natriuretic peptide changes in different periods and different cardiac pacing modes.

Wang R, Li X, Jang W, Liu Z, Yang X, Xiao C, Shao L, Zhu J.

Int Heart J. 2005 Nov;46(6):1015-22. Retraction in: Nagai R. Int Heart J. 2009 May;50(3):405.

Supplemental Content

Support Center